AstraZeneca has revised upward its per-share earnings forecast for 2010 even though revenue growth may be constrained by expected generic competition for the breast cancer drug, Arimidex, and lower pandemic flu vaccine sales. ---Subscribe to MedNous to access this article--- Company News
